Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, CIS, and Australasia. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company also provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, hematology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. It also exports its products worldwide. The company was incorporated in 1949 and is based in Mumbai, India.

Revenue projections:

Revenue projections for IPCALAB
Revenue projections for IPCALAB

Investors may react cautiously to news that Ipca Laboratories Limited's revenues are forecasted to be lower than last year's. Such declines are likely to have a negative effect on the company's bottom line, which can lead to concerns about profitability and hinder investor confidence in the company's future performance.

Financial Ratios:

currentRatio 0.000000
forwardPE 24.073738
debtToEquity 16.246000
earningsGrowth 0.212000
revenueGrowth 0.103000
grossMargins 0.658250
operatingMargins 0.137020
trailingEps 30.690000
forwardEps 47.850000

IPCALAB's Forward PE is in a reasonable range, indicating the stock is priced well relative to its earnings. The stock isn't overpriced, which leaves room for future growth, making it an attractive option for investors seeking value and long-term gains.
Ipca Laboratories Limited's low Debt-to-Equity ratio reflects that the company isn't heavily reliant on debt, reducing financial risk. This conservative approach suggests Ipca Laboratories Limited maintains a stable financial foundation, with greater flexibility to manage future growth or challenges without over-leverage concerns.
IPCALAB's positive earnings and revenue growth signal the company's business is on track for further expansion. These strong financial trends suggest that IPCALAB will continue to grow its operations, driven by increasing profits and revenue.
Ipca Laboratories Limited's forward EPS is greater than its trailing EPS, indicating that the company is expected to deliver higher profitability this year. This suggests that Ipca Laboratories Limited is projected to improve its earnings, reflecting positive growth compared to last year's financial performance.

Price projections:

Price projections for IPCALAB
Price projections for IPCALAB

Ipca Laboratories Limited's price projections have been gradually revised upward, reflecting increased confidence in the company's future performance. This trend suggests analysts expect Ipca Laboratories Limited to achieve greater success in the coming periods.

Insider Transactions:

Insider Transactions for IPCALAB
Insider Transactions for IPCALAB


2 sell transactions of IPCALAB were recorded, with market price hovering near 1465.7999877929688.No sell transactions were carried out during the period under review.With more buying than selling around IPCALAB's current price, investors could be expressing optimism. This trend may suggest that the market expects favorable outcomes for the stock, leading to an increased demand at these levels.

Recommendation changes over time:

Recommendations trend for IPCALAB
Recommendations trend for IPCALAB


Analysts' buy bias for IPCALAB signals that the stock is considered a favorable investment. This outlook might prompt investors to allocate funds to IPCALAB, seeing it as a solid and profitable choice to park their money and potentially benefit from the company's long-term growth.